Compare IBRX & ADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBRX | ADX |
|---|---|---|
| Founded | 2014 | 1840 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | N/A |
| Metric | IBRX | ADX |
|---|---|---|
| Price | $2.32 | $22.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.83 | N/A |
| AVG Volume (30 Days) | ★ 9.5M | 182.4K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.68% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,555,000.00 | N/A |
| Revenue This Year | $629.94 | N/A |
| Revenue Next Year | $109.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1025.95 | N/A |
| 52 Week Low | $1.83 | $14.94 |
| 52 Week High | $5.16 | $19.57 |
| Indicator | IBRX | ADX |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 44.40 |
| Support Level | $2.05 | $22.35 |
| Resistance Level | $2.18 | $23.85 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 83.00 | 18.67 |
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector neutral approach. The fund has a diversified equity portfolio which consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.